Head-to-head trial shows Eli Lilly’s oral GLP-1 orforglipron outperforms oral semaglutide
Scientific American [Unofficial]
February 26, 2026
A new trial found that Eli Lilly’s GLP-1 pill resulted in greater reductions in blood sugar levels and weight than oral semaglutide did, but fewer people stayed on it
Discussion in the ATmosphere